Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Chimeric Antigen Receptor (CAR) – Natural Killer (NK) Cells – Looking good for cancer therapy

By Karen Loudon / November 28, 2023
As published in Drug Target Review  Professor Alan Trounson, AO Dr Huimin Cao Dr Aleta Pupovac The suitability of NK...
Read More

Rearming the body to fight cancer

By Karen Loudon / November 15, 2023
Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian...
Read More

Cartherics announces new capital raise to initiate clinical trials for its lead therapy for ovarian cancer

By Karen Loudon / November 9, 2023
Cartherics is pleased to announce that it is currently undergoing a capital raise, looking to raise up to AU$20 million...
Read More
1 2 3 54